CHO Pharma (6586.TWO) Stock Price

CHO Pharma, Inc. develops and commercializes innovative biopharmaceutical products using proprietary glycan engineering technologies. The company focuses on eight technology categories: homogeneous antibody drugs, monoclonal antibodies for cancers and immune-related diseases, carbohydrate-related vaccines and drugs, anti-influenza drugs, Saccharin tablets, sugar probes, sugar molecular synthesis and identification, and derivative patents of innovation development plans. These products are targeted at medical and pharmaceutical markets requiring advanced therapeutic solutions. The company's revenue streams come from the development and commercialization of these specialized biopharmaceutical products. Its primary customers are healthcare providers, hospitals, and pharmaceutical distributors seeking advanced treatments for cancer, immune disorders, and infectious diseases. The company's technology segments include antibody therapies, vaccine development, and antiviral drug applications, all leveraging its glycan engineering platform. CHO Pharma's business model centers on leveraging its patented glycan engineering technologies to create and sell high-value pharmaceutical products. The company's product portfolio spans multiple therapeutic areas, including oncology, immunology, and virology, with a focus on developing innovative treatments that address unmet medical needs. Its commercialization strategy involves direct sales to healthcare institutions and partnerships with pharmaceutical distributors for broader market reach.